Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Protocol No. CKAE609X2201 A proof-of-concept open label, 3-day repeated dose study to assess efficacy, safety, tolerability and pharmacokinetics of KAE609 in adult patients with acute, uncomplicated Plasmodium falciparum or vivax malaria mono-infection

Leong, Franz Joel Wen and Lefevre, Gilbert and Magnusson, Baldur (2014) Protocol No. CKAE609X2201 A proof-of-concept open label, 3-day repeated dose study to assess efficacy, safety, tolerability and pharmacokinetics of KAE609 in adult patients with acute, uncomplicated Plasmodium falciparum or vivax malaria mono-infection. New England Journal of Medicine.

Abstract

Not applicable.
This is a redacted protocol for inclusion in the online supplementary materials accompanying the manuscript entitled 'The novel spiroindolone KAE609 clears parasitemia rapidly in Falciparum and Vivax malaria'

Item Type: Article
Date Deposited: 13 Oct 2015 13:13
Last Modified: 13 Oct 2015 13:13
URI: https://oak.novartis.com/id/eprint/21205

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.